Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis (Phase 2)
2020-004001-32Phase 2Active
- Sponsor
- European Myeloma Network
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin in light-chain amyloidosis, sponsored by European Myeloma Network. Primary endpoint: CR/VGPR/low-dFLC response rate at 6 months. Started Dec 2020; status: active.
02
Drugs
belantamab mafodotin
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2020-004001-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004001-32.